Is ibogaine approved for depression in the United States?
No. Ibogaine is not an approved depression medicine in the United States and remains Schedule I federally. Its use for depression is investigational and outside standard care.
Investigational treatment context
Ibogaine Treatment For Depression
Ibogaine is being studied as a possible rapid-acting option for severe, treatment-resistant depression. The interest is real; so are the limits of the evidence and the safety concerns.
Ibogaine is a naturally occurring psychoactive compound derived from the iboga plant. Its metabolite, noribogaine, is thought to contribute to longer-lasting effects. In the depression context, ibogaine is being studied for treatment-resistant depression, often alongside PTSD, anxiety, and traumatic brain injury—not as routine first-line depression care.
Interest has grown because the treatment is sometimes framed as a rapid, single-session option for people whose depression has not responded to standard approaches. But ibogaine is not an approved depression medicine in the United States. It remains Schedule I federally, as described in the DEA’s drug scheduling framework, and general medical use is still outside standard care.
“Ibogaine treatment” usually means a medically supervised protocol with cardiac screening and monitoring, often in research settings or offshore clinics. It should not be understood as casual psychedelic use. The compound’s history, chemistry, and plant origin are outlined in the ibogaine reference overview, but a reference entry does not establish clinical effectiveness.
The strongest human findings for depression come from a small open-label Stanford study in veterans with traumatic brain injury. That study reported large short-term changes in depression, PTSD, and anxiety symptoms. Stanford’s own account of how ibogaine may inspire new treatments for addiction and depression reflects why the research has attracted attention.
What the research says
Promising signals, not settled proof
Small, open-label datasets can identify a signal worth studying. They cannot by themselves show how ibogaine compares with placebo, other treatments, careful selection, or the wider treatment setting.
Findings that draw attention
In Stanford’s 2024 veteran study, average symptom reductions at one month were reported as 88% for PTSD, 87% for depression, and 81% for anxiety. The study included 30 veterans and used ibogaine combined with magnesium. No serious side effects or cardiac events were reported in that cohort.
A 2026 follow-up analysis reported sustained remission probabilities at 12 months of 66% for depression and 61% for anxiety in a magnesium-ibogaine dataset. Those outcomes are notable, but they do not remove the need for controlled research. A recent clinical literature analysis of ibogaine adds to a still-developing record rather than closing the question.
What the evidence cannot yet answer
A review of research from 1990 to February 2025 included 24 studies and 38 case reports or series, emphasizing the limited evidence base. It concluded that no double-blind randomized controlled trial had demonstrated efficacy for opioid use disorder and that evidence remains exploratory for psychiatric indications, including depression.
That distinction matters. Open-label studies can be affected by expectations, selection, co-occurring care, and the absence of a comparison group. The National Institute of Mental Health explains the role of evidence-based depression care in a broader treatment context; investigational findings should be weighed against that standard.
“Rapid symptom change is a research signal—not a substitute for safety screening, comparison trials, or careful clinical judgment.”
Why uncertainty belongs in the conversation
Safety and setting
Cardiac risk remains central
Interest in potential benefit should not obscure the practical reality: ibogaine can carry serious risks, and a medically supervised protocol is materially different from unsupervised use.
Screening is not a formality
Ibogaine can affect cardiac rhythm. This is why cardiac history, medication review, testing, and monitoring are central to discussions of safety. The U.S. Food and Drug Administration’s guidance on drug-induced arrhythmias illustrates why rhythm-related risks require serious attention in drug development and clinical decision-making.
People considering investigational treatment should understand how ibogaine is administered, what monitoring is offered, and what happens if complications arise. A practical explanation of how ibogaine is administered can help clarify the questions a supervised protocol should be able to answer.
Location does not replace diligence
Because ibogaine is not approved for general medical use in the United States, some people look to treatment settings abroad. Information about ibogaine centers in Mexico may be part of that search, but location alone does not demonstrate quality, safety, legality, or suitability for any individual.
Anyone reviewing options should distinguish a description of facilities from evidence that a protocol is appropriate. Comparing what ibogaine treatment facilities say about screening, monitoring, and emergency planning is more useful than treating any single claim as assurance.
A practical frame
Questions worth asking before conclusions
What does the evidence actually show? Who was studied? Was there a control group? What screening was performed? What other care was provided? What remains unknown? Understanding what ibogaine does begins with these questions, not with a promise of a result.
Policy and access
Why the topic is moving into wider view
Policy interest, expanded trial plans, and public attention have increased the visibility of ibogaine. Visibility is not the same as clinical consensus.
Research and policy attention
Ibogaine moved from fringe discussion to a more policy-relevant topic as federal and state actors elevated psychedelic research and access pathways. U.S. trials are expanding, and Texas awarded $50 million to UTMB and UTHealth Houston to lead ibogaine clinical trials. This signals mainstream interest in finding clearer answers, not proof that the treatment is ready for routine use.
For people trying to understand the legal and practical landscape, the question of ibogaine in the United States requires attention to federal status, state activity, research participation, and the difference between investigational access and standard medical care.
Context around depression claims
Some providers and information pages discuss ibogaine in relation to anxiety and depression. A description of anxiety and depression treatment claims may show how the therapy is discussed publicly, but these claims should be separated from controlled clinical evidence.
Supplement-related language can create further confusion. The discussion of ibogaine supplements is not evidence that an unregulated product is safe, effective, or comparable to a medically supervised research protocol.
About this resource
Koru Vale helps people understand the evolving evidence, risks, policy, and practical questions around investigational ibogaine use for depression. Our approach to independence and uncertainty explains how we frame information, while the guidance and resource scope clarifies the practical context we can offer. We are not a clinic or treatment provider.
Common questions
FAQ
Clear answers to the limits, findings, and safety issues most often raised around ibogaine for depression.
What is the strongest human evidence?
The strongest human evidence comes from a small open-label Stanford study in 30 veterans with traumatic brain injury. It reported large short-term reductions in depression symptoms, but the overall evidence base remains thin.
Why is cardiac screening so important?
Ibogaine can affect cardiac rhythm. Medical screening and monitoring are central safety considerations, and people should not treat investigational use as casual psychedelic use.
Do offshore treatment options change the evidence?
No. Settings outside the United States may be part of a person’s search, including information about ibogaine treatment in Costa Rica, but geography does not resolve questions about medical suitability, screening quality, or efficacy.